Double Medical(002901)2025-01-10 10:15Financial Performance - The net profit attributable to shareholders is expected to be between 35,000 and 39,000 million CNY, representing a growth of 493.50% to 561.33% compared to the same period last year, which was 5,897.25 million CNY[3] - The net profit after deducting non-recurring gains and losses is projected to be between 28,000 and 32,000 million CNY, indicating a significant increase of 2,552.75% to 2,931.71% from last year's figure of 1,055.51 million CNY[3] - The basic earnings per share is anticipated to be between 0.85 and 0.94 CNY, compared to 0.14 CNY in the same period last year[3] Business Strategy - The company has adjusted its business strategy in response to the implementation of orthopedic consumables procurement policies, leading to a gradual recovery in the orthopedic business line[6] - The company has continued to expand its non-orthopedic consumables categories, achieving good growth in minimally invasive surgery, dental, and neurosurgery product lines[6] Financial Reporting - The financial data presented is based on preliminary estimates by the company's finance department and has not yet been audited[4] - There are no discrepancies between the company and the accounting firm regarding the performance forecast[5] - Investors are advised to exercise caution as the performance forecast is subject to change and the final financial data will be disclosed in the 2024 annual report[7]